Ember Therapeutics is a product-focused company translating its world-class biology in the emerging area of brown fat into a proprietary pipeline of peripherally-acting treatments for metabolic disease, including Type 2 diabetes and obesity.

07.24.13
C. Ronald Kahn, M.D., Receives Wallace H. Coulter Lectureship Award Read More

 

05.17.13
Vamsi Mootha named an HHMI Investigator Read More

 

10.04.12
Ember Therapeutics Broadens Brown Fat Small Molecule Drug Discovery Portfolio, Secures Exclusive License Options to Intellectual Property for Three Small Molecule Targets Read More